無料プレビュー

Alkermes plc (ALKS) · NASDAQ

プロフィール

Alkermes plc is a global biopharmaceutical company developing innovative medicines in neuroscience for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. Its proprietary commercial products include ARISTADA, LYBALVI, VIVITROL, and LUMRYZ, marketed primarily in the U.S. through its own sales force. The company also receives royalties and manufacturing revenues from third-party licensees commercializing products incorporating its proprietary technologies, including long-acting injectables marketed by Janssen and VUMERITY by Biogen. Alkermes manufactures mos

主要指標

株価: $40.11 (-3.22%)
時価総額: 67億ドル
PER（今期予想）: -75.4
PBR: 3.7
配当利回り: —
52週レンジ: $27.00 – $55.67
業種: Healthcare / Drug Manufacturers - Specialty & Generic
上場: NASDAQ
構成銘柄: —

比較会社: TAK Takeda Pharmaceutical Company Limited、TEVA Teva Pharmaceutical Industries Limited、HLN Haleon plc、ZTS Zoetis Inc.、VTRS Viatris Inc.、NBIX Neurocrine Biosciences, Inc.、ITCI Intra-Cellular Therapies, Inc.、JAZZ Jazz Pharmaceuticals plc

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-10-28 · 更新: 2026-10-09